Roche Holding (OTC: RHHBY) and Gilead Sciences (NASDAQ: GILD) both saw increased sales during the pandemic, due in part to their COVID-19 products. For Gilead, it was its COVD-19 antiviral, Veklury, and for Roche, its revenue was boosted mostly by coronavirus tests.

Now the large-cap drug companies are looking for growth beyond COVID-19 sales. Gilead's shares have glittered in 2022, with the stock up more than 16%, while Roche's have fallen more than 23% so far this year. The question is, which healthcare stock is the better buy now?

Gilead reported third-quarter revenue of $6.99 billion, down 5%, year over year, and earnings per share (EPS) of $1.42, down from $2.05 in the third quarter of 2021. Through nine months, Gilead's revenue of $19.9 billion represents a drop of 1% over 2021. 

Continue reading

Source Fool.com